Syros Pharmaceuticals, Inc. 4
4 · Syros Pharmaceuticals, Inc. · Filed Feb 13, 2017
Insider Transaction Report
Form 4
Kuvalanka Kyle D.
Chief Operating Officer
Transactions
- Award
Stock Option (right to buy)
2017-02-10+78,000→ 78,000 totalExercise: $10.90Exp: 2027-02-09→ Common Stock (78,000 underlying)
Footnotes (1)
- [F1]This option becomes exercisable as to 25% of the shares underlying the award on February 10, 2018, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter.